Literature DB >> 1473615

Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.

A J Jenkins1, J S Steele, E D Janus, J D Santamaria, J D Best.   

Abstract

Patients with Type 2 (non-insulin-dependent) diabetes mellitus complicated by microalbuminuria or albuminuria, have an increased risk of developing macrovascular disease and of early mortality. Because lipoprotein abnormalities have been associated with diabetic nephropathy, this study tested the hypothesis that levels of apolipoprotein (a) are elevated in patients with Type 2 diabetes and increased levels of urinary albumin loss. Levels of apolipoprotein (a) in diabetic patients with microalbuminuria (n = 26, geometric mean 195 U/l, 95% confidence interval 117-324) and albuminuria (n = 19, 281 U/l, 165-479) were higher than in non-diabetic control subjects (n = 140, 107 U/l, 85-134, p < 0.05), and in the albuminuric group than diabetic patients without urinary albumin loss (n = 58, 114 U/l, 76-169, p < 0.05). Patients with microalbuminuria and albuminuria had levels comparable with patients undergoing elective coronary artery graft surgery (n = 40, 193 U/l, 126-298). Apolipoprotein (a) levels were higher in diabetic patients with macrovascular disease than in those without (n = 49, 209 U/l, 143-306 vs n = 54, 116 U/l, 78-173, p < 0.05). These preliminary results suggest that raised apolipoprotein (a) levels of Type 2 diabetic patients with microalbuminuria and albuminuria may contribute to their propensity to macrovascular disease and early mortality.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473615     DOI: 10.1007/bf02221681

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  32 in total

1.  Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.

Authors:  J S Yudkin; R D Forrest; C A Jackson
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

Review 2.  Lipids and the kidney.

Authors:  B L Kasiske; M P O'Donnell; W Cowardin; W F Keane
Journal:  Hypertension       Date:  1990-05       Impact factor: 10.190

3.  Transient changes of serum lipoprotein(a) as an acute phase protein.

Authors:  S Maeda; A Abe; M Seishima; K Makino; A Noma; M Kawade
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

4.  A potential basis for the thrombotic risks associated with lipoprotein(a).

Authors:  L A Miles; G M Fless; E G Levin; A M Scanu; E F Plow
Journal:  Nature       Date:  1989-05-25       Impact factor: 49.962

5.  Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes.

Authors:  S M Haffner; K R Tuttle; D L Rainwater
Journal:  Metabolism       Date:  1992-02       Impact factor: 8.694

6.  The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity.

Authors:  G B Appel; C B Blum; S Chien; C L Kunis; A S Appel
Journal:  N Engl J Med       Date:  1985-06-13       Impact factor: 91.245

7.  A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis.

Authors:  P Költringer; G Jürgens
Journal:  Atherosclerosis       Date:  1985-12       Impact factor: 5.162

8.  Lipoprotein(a) levels in black and white children and adolescents with IDDM.

Authors:  L L Levitsky; A M Scanu; S H Gould
Journal:  Diabetes Care       Date:  1991-04       Impact factor: 19.112

9.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

10.  Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria.

Authors:  H Kapelrud; H J Bangstad; K Dahl-Jørgensen; K Berg; K F Hanssen
Journal:  BMJ       Date:  1991-09-21
View more
  19 in total

1.  Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.

Authors:  Lin Ding; An Song; Meng Dai; Min Xu; Wanwan Sun; Baihui Xu; Jichao Sun; Tiange Wang; Yu Xu; Jieli Lu; Weiqing Wang; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2015-02-03       Impact factor: 5.922

Review 2.  New concepts in diabetes mellitus. II: Complications.

Authors:  M Vanderpump; R Taylor
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

3.  Development and validation of a self-assessment tool for albuminuria: results from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Paul Muntner; Mark Woodward; April P Carson; Suzanne E Judd; Emily B Levitan; Devin M Mann; William McClellan; David G Warnock
Journal:  Am J Kidney Dis       Date:  2011-05-26       Impact factor: 8.860

Review 4.  Diabetic dyslipidaemia: current treatment recommendations.

Authors:  J D Best; D N O'Neal
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

Review 5.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

6.  Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients.

Authors:  K Hirata; K Saku; S Jimi; S Kikuchi; H Hamaguchi; K Arakawa
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

7.  Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

Authors:  F S Nielsen; A I Voldsgaard; M A Gall; P Rossing; E Hommel; P Andersen; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

8.  Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes.

Authors:  J Ruiz; J Thillet; T Huby; R W James; D Erlich; P Flandre; P Froguel; J Chapman; P Passa
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

9.  Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.

Authors:  Timothy J Lyons; Alicia J Jenkins
Journal:  Diabetes Rev (Alex)       Date:  1997

Review 10.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.